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Introduction
Klebsiella pneumoniae (K. pneumoniae) is Gram-negative, rod-
shaped, facultative anaerobic, and nonmotile bacterium, belongs to 
family Enterobacteriaceae. It is a common human pathogen associated 
with nosocomial and community infections [1]. K. pneumoniae isolates 
causes several infections such as pneumonia, septicemia, wound 
infections, and urinary tract infections, which ultimately lead to 
morbidity and mortality especially in immunocompromised patients, 
and patients of intensive care units, pediatrics and surgical wards [2]. 
K. pneumoniae acquire resistance against existing antimicrobials by 
multiple mechanism results in increased multidrug-resistant (MDR) 
of K. pneumoniae that leads to serious problem in hospital settings 
and health concern. Emergence of resistance occurs not only in 
MDR isolates but also exist in pan-drug resistant (PDR) isolates of K. 
pneumoniae. PDR refers to the resistant strains those are specifically 
resistant to 7 antimicrobial agents such as cefepime, imipenem, 
meropenem, ceftazidime, ciprofloxacin, piperacillin-tazobactam, 
and levofloxacin [3]. Apart from this, the extended-spectrum 
β-lactamase (ESBL) producing Klebsiella from a patient has been 
identified which causes serious threat worldwide [4,5]. Continuous 
use of antibiotics leads to resistance in microorganisms via. different 
pathways mediated by plasmids, transposons, and gene cassettes in 
integrons [6,7]. Carbapenem is usually preferred for the infection 
caused by MDR isolates of K. pneumoniae but recently carbapenem-
resistant K. pneumoniae was also reported [8]. Due to dramatically 
increase in drug resistant in K. pneumoniae, very few treatment 
options are available. Alternative approaches are available but altering 
the sensitivity pattern of antimicrobials using biofield is not available 
against MDR microorganism, apart from existing allopathic system of 
medicine. Biofield treatment may be an alternative approach to alter 
the susceptibility pattern of K. pneumoniae. Complementary and 
alternative medicine (CAM) therapies are commonly practiced in 
healthcare sector and about 36% of Americans regularly uses some form 
of CAM [9]. CAM include numerous energy therapies, biofield therapy, 
is one of the energy medicine widely used worldwide to improve the 
human health. The energy exists in various forms that can be produced 
from different sources such as potential, electrical, kinetic, magnetic, 
and nuclear energy. However, electromagnetic field defines as when 
electrical signals fluctuate will generate magnetic field with respect 
to time. The cumulative effect of bio-magnetic and electric field that 
surrounds the human body is defined as biofield. The biofield energy can 
be monitored by using electromyography (EMG), electrocardiography 
(ECG) and electroencephalogram (EEG) [10]. According to Lucchetti 
et al. biofield energy has shown significant effect on growth of bacterial 
cultures [11]. Mr. Trivedi has the ability to harness the energy from 
environment or universe and can transmit into any living or nonliving 
object(s) around the Universe. The objects always receive the energy 
and responding into useful way via biofield energy and the process is 
known as biofield treatment. Mr. Trivedi’s unique biofield treatment is 
also known as The Trivedi Effect®. Mr. Trivedi’s biofield treatment was 
extensively studied in different fields such as in material science [12,13], 
agricultural science [14-16], and in biotechnology [17]. Further, 
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the biofield treatment has considerably altered the susceptibility of 
antimicrobials and biotype of microbes [18-20]. By considering the 
above mentioned facts and literature reports on biofield treatment, 
the present work was undertaken to evaluate the impact of biofield 
treatment on antimicrobials susceptibility, biochemical reactions 
pattern, and biotype of MDR isolates of K. pneumoniae.
Materials and Methods
Experimental design and bacterial isolates
MDR clinical lab isolates (i.e. LS 2, LS 6, LS 7 and LS 14) of K. 
pneumoniae were obtained from stored stock cultures in Microbiology 
Lab, Hinduja Hospital, Mumbai. Each MDR strains was divided 
into two groups i.e. control and treatment. The acceptability of the 
identification media and antimicrobial agents were checked prior to the 
study on microorganisms. The antimicrobial susceptibility, biochemical 
reactions, and biotype number were evaluated on MicroScan Walk-
Away® (Dade Behring Inc., West Sacramento, CA) using Negative 
Breakpoint Combo 30 (NBPC 30) panel. The NBPC 30 panel was stored 
at 2 to -25ºC. All antimicrobials and biochemicals were procured from 
Sigma Aldrich, USA.
Biofield treatment strategy 
Treatment groups of each strain, in sealed pack were handed over 
to Mr. Trivedi for biofield treatment under laboratory conditions. Mr. 
Trivedi provided the treatment through his energy transmission process 
to the treated groups without touching the samples. The biofield treated 
samples were returned in the similar sealed condition and analyzed 
on day 10 using the standard protocols. The study was conducted on 
automated MicroScan Walk-Away® system (Dade Behring Inc., USA). 
Evaluation of antimicrobial susceptibility assay
Antimicrobial susceptibility patterns of MDR lab isolates of K. 
pneumoniae were studied using MicroScan Walk-Away® using Negative 
Break Point Combo (NBPC 30) panel as per manufacturer’s instructions. 
The antimicrobial susceptibility pattern (S: Susceptible, I: Intermediate, 
IB: Inducible β-lactamase; EBL: Suspected extended-spectrum β 
-lactamases, and R: Resistant) and MIC values were determined by 
observing the lowest antimicrobial concentration showing growth 
inhibition [21]. The antimicrobials used in the susceptibility assay viz. 
amikacin, amoxicillin/k-clavulanate, ampicillin/sulbactam, ampicillin, 
aztreonam, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, 
ceftazidime, ceftriaxone, cefuroxime, cephalothin, chloramphenicol, 
ciprofloxacin, gatifloxacin, gentamicin, imipenem, levofloxacin, 
meropenem, moxifloxacin, norfloxacin, nitrofurantoin piperacillin, 
piperacillin/tazobactam, tetracycline, ticarcillin/K-clavulanate, 
tobramycin, and trimethoprim/sulfamethoxazole 
Biochemical study 
Biochemical studies of each MDR isolates of K. pneumoniae were 
determined by MicroScan Walk-Away® using NBPC 30 panel system 
in both control and treated groups. Biochemicals used in the study 
are acetamide, adonitol, arabinose, arginine, cetrimide, cephalothin, 
citrate, colistin, esculin hydrolysis, nitrofurantoin, glucose, hydrogen 
sulfide, indole, inositol, kanamycin, lysine, malonate, melibiose, nitrate, 
oxidation-fermentation, galactosidase, ornithine, oxidase, penicillin, 
raffinose, rhamnose, sorbitol, sucrose, tartarate, tryptophan deaminase, 
tobramycin, urea, and Voges-Proskauer [21].
Identification by biotype number
The biotype number of each MDR isolates of K. pneumoniae in 
control and treated sample were determined followed by identification 
of microorganism by MicroScan Walk-Away® processed panel data 
report with the help of biochemical reaction data [21].
Results and Discussion
Antimicrobial susceptibility study
Results of antimicrobial sensitivity pattern and MIC values of 
control and treated MDR isolates of K. pneumoniae are summarized 
in Tables 1 and 2, respectively. All these changes were observed on 10 
days after biofield treatment as compared to control group. Overall, 
46.42% of tested antimicrobials out of twenty eight, showed alteration 
in antimicrobial sensitivity pattern against biofield treated MDR 
isolates of K. pneumoniae. All four MDR isolates, showed variations 
in antimicrobial sensitivity assay viz. 32.14% in LS 2, 25% in LS 6, 
17.85% in LS 7, and 28.57% in LS 14 against the tested antimicrobials 
(Figure 1). Extended spectrum beta-lactamases (ESBLs) are rapidly 
evolved group of beta-lactamases enzyme, which confer resistance to 
most beta-lactam antibiotics, including penicillins, cephalosporins, 
monobactam and aztreonam. Apart from beta-lactam antibiotics, 
ESBLs are also resistant to other classes of non-penicillin antibiotics 
[22]. Beta-lactamases are enzymes that inactivates the antibiotic and are 
present in almost all Gram-negative bacilli. However, some pathogenic 
species, such as E. coli and Klebsiella spp., are not able to induce the 
production of β-lactamase which varies from low to high level. In 
some species, exposure to β-lactams will induced the production level 
of β-lactamase, commonly results in resistance to these agents. These 
inducible β-lactamases are frequently found in Enterobacter spp. [23]. 
Experimental results of antimicrobial sensitivity assay showed altered 
sensitivity pattern in biofield treated clinical isolates of K. pneumonia. 
Aztreonam, cefotaxime, ceftazidime, and ceftriaxone sensitivity 
changed from EBL → R in LS 2 and LS 14. Sensitivity of amoxicillin/k-
clavulanate changed from S → R in LS 7 and LS 14, while S → IB and 
I → R in LS 2 and LS 6 respectively. Cefotetan and cefoxitin found 
changed sensitivity pattern from S → R in LS 7, and while S → IB in 
LS 2. Sensitivity of cefotetan changed from I → R in LS 6 while S → 
IB in LS 14. Chloramphenicol and imipenem sensitivity changed from 
S → R in LS 6. Although, in imipenem sensitivity changed from S → 
I in LS 6. Meropenem sensitivity changed from I → R and S → R in 
LS 6 and LS 7 respectively. An increase in sensitivity was reported in 
piperacillin/tazobactam and piperacillin i.e. from R → I in biofield 
treated LS 6 as compared to control. Although, piperacillin/tazobactam 
sensitivity changed from S → IB and S → I in LS 2 and LS 14 respectively. 
Ticarcillin/K-clavulanate sensitivity altered from S → I and S → R in LS 
2 and LS 14 respectively (Table 1). Rest of antimicrobials did not show 
any change in sensitivity pattern after biofield treatment. 
Determination of Minimum Inhibitory Concentration (MIC)
MIC values of all the clinical MDR isolates of control and biofield 
treated K. pneumoniae are summarized in Table 2. MIC values were 
decreased in case of piperacillin/tazobactam and piperacillin in LS 
6 isolate only, while in rest of the antimicrobials, MIC values were 
increased as compared to control. Overall, MIC results showed an 
alteration in 30% tested antimicrobials (i.e. nine out of thirty) after 
biofield treatment in clinical isolates of K. pneumoniae (Table 2 and 
Figure 1). A decreased in MIC values in piperacillin/tazobactam and 
piperacillin were reported along with increases antimicrobial sensitivity 
after biofield treatment (64 µg/ml) in LS 6. Current treatment strategy 
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S. No. Antimicrobial
LS 2 LS 6 LS 7 LS 14
C T C T C T C T
1 Amikacin S S R R R R S S
2 Amoxicillin/k-clavulanate S IB I R S R S R
3 Ampicillin/sulbactam R R R R R R R R
4 Ampicillin R R R R R R R R
5 Aztreonam EBL R EBL EBL EBL EBL EBL R
6 Cefazolin R R R R R R R R
7 Cefepime R R R R R R R R
8 Cefotaxime EBL R EBL EBL EBL EBL EBL R
9 Cefotetan S IB I R S R S IB
10 Cefoxitin S IB R R S R R R
11 Ceftazidime EBL R EBL EBL EBL EBL EBL R
12 Ceftriaxone EBL R EBL EBL EBL EBL EBL R
13 Cefuroxime R R R R R R R R
14 Cephalothin R R R R R R R R
15 Chloramphenicol S S S R R R I I
16 Ciprofloxacin S S R R R R R R
17 Gatifloxacin S S R R R R R R
18 Gentamicin R R R R R R R R
19 Imipenem S S S R S I S S
20 Levofloxacin S S R R R R R R
21 Meropenem S S I R S R S S
22 Moxifloxacin S S R R R R R R
23 Piperacillin R R R I R R R R
24 Piperacillin/tazobactam S IB R I R R S I
25 Tetracycline S S R R R R R R
26 Ticarcillin/k-clavulanate S I R R R R S R
27 Tobramycin R R R R R R R R
28 Trimethoprim/sulfamethoxazole S S R R R R R R
C: Control; T: Treatment; R: Resistant; I: Intermediate; S: Susceptible; LS: Lab Isolate; EBL: Suspected extended-spectrum beta-lactamases
Table 1: Effect of biofield treatment on multidrug resistant lab isolates of Klebsiella pneumoniae to antimicrobial susceptibility.
against K. pneumoniae infections preferably uses cefoperazone/
sulbactam, piperacillin/tazobactam, and imipenem antimicrobials 
[24]. Although, piperacillin/tazobactam antimicrobial agent is useful 
and preferred in neonatal infections caused due to K. pneumoniae [25]. 
Biofield treatment in clinical isolate (LS 6) significantly increased the 
sensitivity and decreased the MIC values of piperacillin/tazobactam 
and piperacillin. In Enterobacteriaceae family, the most prevalent 
mechanism of acquired resistance in β-lactam antibiotics (piperacillin/
tazobactam and piperacillin) are the production of β-lactamases [26]. 
Biofield treatment might act on enzymatic or genetic level which might 
affects the β-lactamases production that may lead to alter the sensitivity 
pattern of tested antimicrobials. 
Biochemical and biotype number study
Biochemical study results of control and biofield treated groups 
are summarized in Table 3 and Figure 1. Results showed that overall 
15.15% change in tested biochemical reactions among 4 treated MDR 
clinical isolates of K. pneumoniae as compared to control. Cetrimide 
changed from (-) negative to (+) positive reaction in LS 6, LS 7, and LS 
14 as compared to control. Voges-Proskauer changed from (+) positive 
to (-) negative reaction in LS 2, LS 6, and LS 7. Indole changed from 
(+) positive to (-) negative reaction in LS 7. Ornithine changed from 
negative (-) to positive (+) reaction in LS 14. Rest of biochemicals did 
not show any alteration in their reaction after biofield treatment. Voges-
Proskauer, citrate, arabinose, lysine, glucose, sucrose, malonate are the 
standard positive reaction biochemical tests of K. pneumoniae while 
hydrogen sulfide, indole, ornithine and cetrimide are the standard 
negative reaction test. Biochemical reactions of control MDR isolates 
of K. pneumoniae were well supported with literature data [27]. Based 
on the biochemical results, significant alteration in biotype numbers 
were observed in all the four biofield treated lab isolates i.e. LS 2, LS 6, 
LS 7, and LS 14 as compared to control. New organism was identified 
as Enterobacter aerogenes in LS 2 and LS 14 after biofield treatment 
on day 10 with respect to control (Table 4). Biofield treatment as 
an alternate and complementary medicine, increasingly used in 
biomedical health care system such as reduction in pain and anxiety 
[28]. However, National Center for Complementary and Alternative 
Medicine/National Institute of Health (NCCAM/NIH), now defined 
biofield therapies in subcategory of energy therapies as one of the 
five complementary medicine domain [29]. Mr. Trivedi’s biofield 
treatment in pathogenic microbes were extensively studied and had 
shown significant alteration in the antimicrobial sensitivity pattern, 
biochemical reactions, and biotype number [18,19]. Biofield treatment 
might be responsible to do alteration in microorganism at genetic level 
and/or enzymatic level, which may act on receptor protein. While 
altering receptor protein, ligand-receptor/protein interactions may 
also alter that could lead to show different phenotypic characteristics. 
Hence a cascade of intra-cellular signals may be initiated, accelerated or 
inhibited [30]. The overall observations showed that, biofield treatment 
on MDR isolates of K. pneumoniae induced significant alteration in 
antimicrobial susceptibility pattern, MIC values, biochemical reactions, 
and biotype number. 
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S. No. Antimicrobial
LS 2 LS 6 LS 7 LS 14
C T C T C T C T
1 Amikacin ≤16 ≤16 >32 >32 >32 >32 ≤16 ≤16
2 Amoxicillin/ Clavulanic acid ≤8/ 4 ≤8/4 16/8 >16/8 ≤8/4 >16/8 ≤8/4 >16/8
3 Ampicillin/Sulbactam >16/8 >16/8 >16/8 >16/8 >16/8 >16/8 >16/8 >16/8
4 Ampicillin >16 >16 >16 >16 >16 >16 >16 >16
5 Aztreonam >16 >16 >16 16 >16 >16 >16 >16
6 Cefazolin >16 >16 >16 >16 >16 >16 >16 >16
7 Cefepime >16 >16 >16 >16 >16 >16 >16 >16
8 Cefotaxime >32 >32 >32 >32 >32 >32 >32 >32
9 Cefotetan ≤16 ≤16 32 >32 ≤16 >32 ≤16 ≤16
10 Cefoxitin ≤8 ≤8 >16 >16 ≤8 >16 >16 >16
11 Ceftazidime >16 >16 >16 >16 >16 >16 >16 >16
12 Ceftriaxone >32 >32 >32 >32 >32 >32 >32 >32
13 Cefuroxime >16 >16 >16 >16 >16 >16 >16 >16
14 Cephalothin >16 >16 >16 >16 >16 >16 >16 >16
15 Chloramphenicol ≤8 ≤8 ≤8 >16 >16 >16 16 16
16 Ciprofloxacin ≤1 ≤1 >2 >2 >2 >2 >2 >2
17 Gatifloxacin ≤2 ≤2 >4 >4 >4 >4 >4 >4
18 Gentamicin >8 >8 >8 >8 >8 >8 >8 >8
19 Imipenem ≤4 ≤4 ≤4 >8 ≤4 8 ≤4 ≤4
20 Levofloxacin ≤2 ≤2 >4 >4 >4 >4 >4 >4
21 Meropenem ≤4 ≤4 8 >8 ≤4 >8 ≤4 ≤4
22 Moxifloxacin ≤2 ≤2 >4 >4 >4 >4 >4 >4
23 Nitrofurantoin ≤32 ≤32 >64 >64 >64 >64 ≤32 ≤32
24 Norfloxacin ≤4 ≤4 >8 >8 >8 >8 >8 >8
25 Piperacillin >64 >64 >64 64 >64 >64 >64 >64
26 Piperacillin/Tazobactam ≤16 ≤16 >64 64 >64 >64 ≤16 64
27 Tetracycline ≤4 ≤4 >8 >8 >8 >8 >8 >8
28 Ticarcillin/K-Clavulanate ≤16 64 >64 >64 >64 >64 ≤16 >64
29 Tobramycin >8 >8 >8 >8 >8 >8 >8 >8
30 Trimethoprim/Sulfamethoxazole ≤2/38 ≤2/38 >2/38 >2/38 >2/38 >2/38 >2/38 >2/38
MIC values are presented in µg/ml; C: Control; T: Treatment; LS: Lab Isolate
Table 2: Minimum inhibitory concentration (MIC) of multidrug resistant lab isolates of Klebsiella pneumoniae.
 
 
 
 
 
 
 
Figure 1: Percentage change in antimicrobial sensitivity pattern, minimum inhibitory concentrations and biochemical reactions after biofield treatment in multi-drug 
resistant lab isolates of Klebsiella pneumonia.
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S. No. Code Biochemical
LS 2 LS 6 LS 7 LS 14
C T C T C T C T
1 ACE Acetamide - - - - - - - -
2 ADO Adonitol + + + + + + + +
3 ARA Arabinose + + + + + + + +
4 ARG Arginine - - - - - - - -
5 CET Cetrimide - - - + - + - +
6 CF8 Cephalothin + + + + + + + +
7 CIT Citrate + + + + + + + +
8 CL4 Colistin - - - - - - - -
9 ESC Esculin hydrolysis + + + + + + + +
10 FD64 Nitrofurantoin - - + + + + - -
11 GLU Glucose + + + + + + + +
12 H2S Hydrogen sulfide - - - + - - - -
13 IND Indole - - - - + - - -
14 INO Inositol + + + + + + + +
15 K4 Kanamycin + + + + + + + +
16 LYS Lysine + + + + + + + +
17 MAL Malonate + + + + + + + +
18 MEL Melibiose + + + + + + + +
19 NIT Nitrate + + + + - - + +
20 OF/G Oxidation-Fermentation + + + + + + + +
21 ONPG Galactosidase + + + + - - + +
22 ORN Ornithine - - - - - - - +
23 OXI Oxidase - - - - - - - -
24 P4 Penicillin + + + + + + + +
25 RAF Raffinose + + + + + + + +
26 RHA Rhamnose + + + + + + + +
27 SOR Sorbitol + + + + + + + +
28 SUC Sucrose + + + + + + + +
29 TAR Tartrate + + + + - - - -
30 TDA Tryptophan Deaminase - - - - - - - -
31 TO4 Tobramycin + + + + + + + +
32 URE Urea - - + + + + + +
33 VP Voges-Proskauer + - + - + - + +
C: Control; T: Treatment; LS: Lab Isolate; -: Negative; +: Positive
Table 3: Effect of biofield treatment on multidrug resistant lab isolates of Klebsiella pneumoniae to the vital processes occurring in living organisms.
Isolate Group Biotype Number Organism Identification
LS 2
C 7770 4372 K. pneumoniae
T 7770 4272 Enterobacter aerogenes
LS 6
C 7774 4372 K. pneumoniae
T 7776 4272 K. pneumoniae
LS 7
C 7774 4362 K. pneumoniae
T 7774 4262 K. pneumoniae
LS 14
C 7774 4372 K. pneumoniae
T 7774 5372 Enterobacter aerogenes
C: Control; T: Treatment; LS: Lab Isolate
Table 4: Effect of biofield treatment on multidrug resistant lab isolates of Klebsiella pneumoniae to distinguishing feature of the genotype 
Conclusion
Overall data conclude that there has a significant impact of 
biofield treatment on antimicrobial susceptibility pattern, MIC values, 
biochemical reactions, and biotype number in all the four clinical 
MDR lab isolates of K. pneumoniae. Based on the study outcome, 
biofield treatment could be applied to alter the sensitivity pattern of 
antimicrobials, against multi-drug resistance isolates of K. pneumoniae.
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